Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bavituximab + gemcitabine
- Development stage
- Unknown
- Lead developer
- Avid Bioservices
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Bavituximab + gemcitabine is an investigational drug combination evaluated for the treatment of advanced stage IV pancreatic cancer. Bavituximab is a chimeric monoclonal antibody that targets phosphatidylserine (PS), a membrane phospholipid externalized on tumor vasculature under stress, promoting antitumor immune responses and potentially enhancing antibody-dependent cellular cytotoxicity on tumor-associated endothelial cells; gemcitabine is a nucleoside analog used as a cytotoxic chemotherapy, primarily inhibiting DNA synthesis in dividing cancer cells. This combination has been investigated in a Phase II clinical trial for pancreatic cancer, demonstrating improved objective response rate and overall survival versus gemcitabine monotherapy, and has shown an acceptable safety profile[1][2][4][3][6].
- Other names
- bavituximab + Gemzar
02
Targets
RNR (Ribonucleotide reductase)B2GP1 (Beta-2-glycoprotein I)DNA polymerase family
Beyond the preview
Go deeper on bavituximab + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bavituximab + gemcitabine.